NCT06638931 2026-04-15ANTARESInstituto do Cancer do Estado de São PauloPhase 2 Recruiting28 enrolled
NCT02834013 2026-04-13Nivolumab and Ipilimumab in Treating Patients With Rare TumorsNational Cancer Institute (NCI)Phase 2 Active not recruiting818 enrolled
NCT06898970 2026-03-17Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for AngiosarcomaUniversity of California, San FranciscoPhase 2 Recruiting18 enrolled